124 related articles for article (PubMed ID: 6546372)
1. Müllerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice.
Fuller AF; Budzik GP; Krane IM; Donahoe PK
Gynecol Oncol; 1984 Jan; 17(1):124-32. PubMed ID: 6546372
[TBL] [Abstract][Full Text] [Related]
2. Subrenal capsule assay to test the viability of parenterally delivered müllerian inhibiting substance.
Donahoe PK; Krane I; Bogdén AE; Kamagata S; Budzik GP
J Pediatr Surg; 1984 Dec; 19(6):863-9. PubMed ID: 6084056
[TBL] [Abstract][Full Text] [Related]
3. Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Fuller AF; Krane IM; Budzik GP; Donahoe PK
Gynecol Oncol; 1985 Oct; 22(2):135-48. PubMed ID: 3932140
[TBL] [Abstract][Full Text] [Related]
4. Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice.
Donahoe PK; Fuller AF; Scully RE; Guy SR; Budzik GP
Ann Surg; 1981 Oct; 194(4):472-80. PubMed ID: 6895157
[TBL] [Abstract][Full Text] [Related]
5. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
Fuller AF; Guy S; Budzik GP; Donahoe PK
J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900
[TBL] [Abstract][Full Text] [Related]
6. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
7. Müllerian-inhibiting substance: an update.
Donahoe PK; Budzik GP; Trelstad R; Mudgett-Hunter M; Fuller A; Hutson JM; Ikawa H; Hayashi A; MacLaughlin D
Recent Prog Horm Res; 1982; 38():279-330. PubMed ID: 6896925
[No Abstract] [Full Text] [Related]
8. Cytotoxic effects of müllerian inhibiting substance (MIS)?
Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W
Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166
[TBL] [Abstract][Full Text] [Related]
9. Production of monoclonal antibodies for affinity purification of bovine mullerian inhibiting substance activity.
Shima H; Donahoe PK; Budzik GP; Kamagata S; Hudson P; Mudgett-Hunter M
Hybridoma; 1984; 3(3):201-14. PubMed ID: 6548727
[TBL] [Abstract][Full Text] [Related]
10. Mullerian inhibiting substance: a fetal hormone with surgical implications.
Hutson JM; Donahoe PK; Budzik GP
Aust N Z J Surg; 1985 Dec; 55(6):599-605. PubMed ID: 2870703
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
12. Enhanced purification of Mullerian inhibiting substance by lectin affinity chromatography.
Budzik GP; Swann DA; Hayashi A; Donahoe PK
Cell; 1980 Oct; 21(3):909-15. PubMed ID: 6893682
[TBL] [Abstract][Full Text] [Related]
13. Insensitivity of the chick embryo müllerian duct to human recombinant müllerian-inhibiting substance.
Weniger JP; Cate RL; Zeis A
J Mol Endocrinol; 1992 Feb; 8(1):73-7. PubMed ID: 1543536
[TBL] [Abstract][Full Text] [Related]
14. Mullerian inhibiting substance fractionation by dye affinity chromatography.
Budzik GP; Powell SM; Kamagata S; Donahoe PK
Cell; 1983 Aug; 34(1):307-14. PubMed ID: 6411352
[TBL] [Abstract][Full Text] [Related]
15. Antibody against avian müllerian inhibiting substance (MIS) recognizes MIS on rat müllerian duct and human tumor cells.
Wang JJ; Teng CS
Proc Natl Sci Counc Repub China B; 1989 Oct; 13(4):267-75. PubMed ID: 2484046
[TBL] [Abstract][Full Text] [Related]
16. Development of mullerian inhibiting substance as an anti-cancer drug.
Cate RL; Ninfa EG; Pratt DJ; MacLaughlin DT; Donahoe PK
Cold Spring Harb Symp Quant Biol; 1986; 51 Pt 1():641-7. PubMed ID: 3472743
[No Abstract] [Full Text] [Related]
17. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat.
Tsuji M; Shima H; Yonemura CY; Brody J; Donahoe PK; Cunha GR
Endocrinology; 1992 Sep; 131(3):1481-8. PubMed ID: 1505479
[TBL] [Abstract][Full Text] [Related]
18. Estrogen inhibition of Mullerian inhibiting substance in the chick embryo.
Hutson JM; Ikawa H; Donahoe PK
J Pediatr Surg; 1982 Dec; 17(6):953-9. PubMed ID: 6897657
[TBL] [Abstract][Full Text] [Related]
19. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
[TBL] [Abstract][Full Text] [Related]
20. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
